Samsung Biologics to acquire PolyPeptide Group in $1.8 billion all-cash deal

Samsung Biologics has announced an all-cash acquisition bid for PolyPeptide Group, a Swiss contract development and manufacturing organization (CDMO), valued at approximately $1.8 billion. The deal is set to expand Samsung Biologics' capabilities in the fast-growing peptide therapeutics market, particularly for obesity drugs. The acquisition will affect PolyPeptide's shareholders, who will receive a cash offer, and positions Samsung Biologics to strengthen its foothold in the CDMO sector. This move matters because it underscores the increasing demand for peptide-based treatments, especially for weight loss and metabolic disorders, and reflects Samsung Biologics' strategy to diversify beyond its core biologics manufacturing. The bid is valued at 2.7 trillion won, as reported by TradingView, and is expected to close pending regulatory approvals. PolyPeptide, known for its expertise in peptide synthesis, has seen rapid growth due to the obesity drug boom. Samsung Biologics, a subsidiary of Samsung Group, has been expanding its CDMO operations globally. The next steps involve due diligence and securing necessary clearances from antitrust authorities, with the deal likely to close in the coming months if approved.